



## Enhancing the efficacy of 5-HT uptake inhibitors in the treatment of attention deficit hyperactivity disorder

Timothy B. Riley\*, Paul G. Overton

Department of Psychology, University of Sheffield, Sheffield S10 2TP, UK



### ABSTRACT

Attention Deficit Hyperactivity Disorder (ADHD) is one of the most common childhood behavioural disorders, the frontline treatments for which are drugs with abuse potential. As a consequence, there is an urgent need to develop non addictive drug treatments with equivalent efficacy. Preclinical evidence suggests that selective serotonin uptake inhibitors (SSRIs) are likely to be effective in ADHD, however clinical reports suggest that SSRIs are of limited therapeutic value for the treatment of ADHD. We propose that this disconnect can be explained by the pattern of drug administration in existing clinical trials (administration for short periods of time, or intermittently) leading to inadequate control of the autoregulatory processes which control 5-HT release, most notably at the level of inhibitory 5-HT<sub>1A</sub> somatodendritic autoreceptors. These autoreceptors reduce the firing rate of 5-HT neurons (limiting release) unless they are desensitised by a long term, frequent pattern of drug administration. As such, we argue that the participants in earlier trials were not administered SSRIs in a manner which realises any potential benefits of targeting 5-HT in the pharmacotherapy of ADHD. In light of this, we hypothesise that there may be under-researched potential to exploit 5-HT transmission therapeutically in ADHD, either through changing the administration regime, or by pharmacological means. Recent pharmacological research has successfully potentiated the effects of SSRIs in acute animal preparations by antagonising inhibitory 5-HT<sub>1A</sub> autoreceptors prior to the administration of the SSRI fluoxetine. We suggest that combination therapies linking SSRIs and 5-HT<sub>1A</sub> antagonists are a potential way forward in the development of efficacious non-addictive pharmacotherapies for ADHD.

### Introduction

Attention Deficit Hyperactivity Disorder (ADHD) is one of the most common childhood behavioural disorders, although estimates of its prevalence vary widely (0.6–29.2%; [1]). This suggests that there is considerable ambiguity in the interpretation of the diagnostic criteria for the disorder and how they relate to the symptoms observed. This ambiguity arises in large part because the pathophysiological basis for the disorder is poorly understood [2]. Pathophysiological uncertainty has also hindered the development of new pharmacotherapies for the disorder, the frontline treatments for which are still amphetamines or methylphenidate (e.g. in the UK, NICE Guideline NG87 [3]), both of which have abuse potential [4]. Although non-stimulant drugs such as atomoxetine are available for the treatment of ADHD, the efficacy of these drugs are poor in comparison to psychostimulants [5] and the search is on for a drug strategy that is as efficacious as psychostimulants without carrying the abuse potential.

Since the seminal work of A.A. Strauss in the 40s and 50's (e.g. [6]), besides hyperactivity, distractibility has been recognised as a core symptom of ADHD. Indeed, increased distractibility is the most frequently presenting symptom of ADHD [7], and is the symptom that shows greatest resistance to extinction with age [8]. On the basis of recent theoretical and experimental work, we have proposed that

increased distractibility in ADHD is caused by a hyper-responsiveness of the superior colliculus (SC; [9]), a visual (superficial layers) and multimodal (deep layers) sensory structure in the midbrain which is intimately linked to eye movements and attentional focus (e.g. [10]). The original case for a collicular sensory hyper-responsiveness in ADHD is made fully in Overton [9], based on clinical observations by other groups and our own early preclinical work. In brief: 1. ADHD patients show increased distractibility in tasks which are sensitive to collicular function; 2. ADHD patients have a general problem inhibiting eye movements (saccades), the generation of which involves the SC; 3. Covert shifts in attention, which have been argued to involve the SC, are also impaired in ADHD; 4. *D*-amphetamine, an effective pharmacotherapeutic agent in ADHD, depresses visually evoked activity in the colliculus; 5. Aberrant reward processing identified in ADHD could also reflect a collicular dysfunction, given the role played by the SC in the regulation of the dopamine systems.

More recently, we have gone on to show that two well validated animal models of ADHD, the Spontaneously Hypertensive Rat and the New Zealand Genetically Hypertensive Rat, both exhibit collicular visual hyper-responsiveness [11,12]. We have also shown that non-clinical human participants who have higher levels of ADHD-like traits exhibit elevated levels of small amplitude saccades at fixation (micro-saccades) compared to those with lower levels of ADHD-like traits [13],

\* Corresponding author.

a saccadic type that is particularly associated with the colliculus (e.g. [14]). Participants with higher levels of ADHD-like traits also process multisensory stimuli abnormally [15], and the SC is acknowledged to play an important role in multisensory integration (e.g. [16]).

### Current pharmacotherapies for ADHD

Identifying the SC as a potential pathological locus of change in ADHD fits well with the known pharmacological actions of frontline ADHD treatments. While the pharmacodynamics of *D*-amphetamine are complex, there is converging evidence that its effects are mediated by elevating synaptic levels of the monoamine neurotransmitters dopamine (DA), noradrenaline (NA) [17] and serotonin (5-HT) [18,19]. *D*-amphetamine affects widespread areas of the brain [17–19], many of which may be involved in the therapeutic effects of the drug, however due to the pathophysiological uncertainty surrounding the disorder, we focus here on the SC. The SC is extensively innervated by 5-HT and NA [20,21], and to a lesser extent by DA [22], and thus expresses the appropriate neurochemistry to allow for the action of *D*-amphetamine (and methylphenidate, a DA/NA/5-HT uptake inhibitor [23]) to be mediated locally within the colliculus. That theoretical possibility was demonstrated to be correct by Dommett et al. [24] using an *in vitro* SC preparation to probe the proximal effects of therapeutically appropriate doses of *D*-amphetamine or methylphenidate applied to the SC. Perfusion of either drug inhibited superficial layer collicular responses to low intensity stimulation of the optic tract, while responses to high intensity stimulation were largely preserved. The inhibitory action of the psychostimulants was blocked by the broad spectrum 5-HT antagonist metergoline, implicating 5-HT in psychostimulant-induced suppression of collicular responsiveness. This suggests that, therapeutically, *D*-amphetamine and methylphenidate may act to enhance 5-HT-mediated modulation of sensory activity at the level of the SC, thereby normalising collicular hypersensitivity and reducing symptoms of distractibility. Although metergoline also interacts with dopamine receptors as well as 5-HT receptors [25] and dopamine receptors are present in the SC [26], the agonistic actions of metergoline appear to be largely confined to D2-type dopamine receptors [27], which are scarce in the superficial layers [22]. The involvement of 5-HT is additionally supported by the finding in Dommett et al. [24] that the inhibitory action of *D*-amphetamine and methylphenidate was mimicked by 5-HT itself. This pharmacological evidence implicating 5-HT in the effects of *D*-amphetamine and methylphenidate at the level of the SC, however, is contradicted by clinical reports that suggest selective serotonin uptake inhibitors (SSRIs) are of limited efficacy in the treatment of ADHD (e.g. [28]). There is therefore a clear disconnect; if collicular dysfunction underlies distractibility in ADHD, and collicular activity is effectively modulated by 5-HT and normalised by psychostimulants, why are SSRIs not more efficacious in treating ADHD?

### Hypothesis

We believe that the low efficacy of SSRIs arises as a result of inadequate control of the autoregulation processes that regulate the release of 5-HT, most notably at the level of inhibitory 5-HT<sub>1A</sub> somatodendritic autoreceptors which limit synaptic release via a reduction in the firing rate of 5-HT neurons. As a consequence, we hypothesise that desensitisation of autoregulation processes, either via an appropriate administration regime for the drug, or via pharmacologically controlling the autoregulatory process, will enhance the efficacy of SSRIs in the treatment of ADHD.

### Serotonin based interventions for ADHD: disconnect between theory and application

There is convergent evidence that frontline ADHD pharmacotherapies may reduce distractibility by targeting 5-HT transmission at

the collicular level (e.g. [24]). However, despite this pharmacological evidence, clinical and behavioural reports assessing the efficacy of SSRIs in the treatment of ADHD have been mixed at best. Trials assessing the viability of treating ADHD with SSRIs were initially promising. In a six week preliminary open trial, ADHD patients who had been non-responsive to stimulants showed at least a moderate improvement in symptoms when treated with fluoxetine [28]. In other trials, however, SSRIs have shown little efficacy in treating ADHD. Donnelly et al. [29] showed that while *D*-amphetamine produced marked improvements in hyperkinetic and inattentive ADHD symptoms, the SSRI fenfluramine did not significantly alter symptom presentation relative to placebo. Similarly, in patients with comorbid ADHD and major depressive disorder, fluoxetine monotherapy produced a remission of depressive symptoms, but had no significant effect on ADHD symptoms [30]. In addition to limited efficacy as a primary treatment for ADHD [28], SSRIs may actually act to exacerbate the symptoms of ADHD. Riddle et al. [32] found that administering fluoxetine to treat children with comorbid ADHD and depression often aggravated ADHD symptoms in a dose dependant manner. Discontinuing fluoxetine treatment reversed this aggravation.

While these trials suggest that SSRIs are of inconsistent therapeutic viability in ADHD [33], it should be noted that each of these studies were comprised of small sample sizes (no trial had more than 20 participants), and that the course of SSRI treatment may have been too short for observable clinical effects [34]. Nevertheless, these early trials have been cited by several major contributors to the field of ADHD psychopharmacology as evidence that the 5-HT system, and drugs that target this system, are of little to no relevance to the treatment of ADHD [35,36]. This, combined with the emergence of other viable alternatives to psychostimulant medication, such as the NA reuptake inhibitor atomoxetine [37,38], has contributed to a period of reduced interest in researching the viability of 5-HT manipulation in the psychotherapy of ADHD.

However, in recent years 5-HT transmission in ADHD has been revisited. Much of this renewed interest stems from advances in genetics, which have revealed that ADHD can be reliably predicted by polymorphisms of the 5-HT transporter (SERT; [39,40]). Specifically, ADHD is associated with a significant over-expression of the long variant of the promoter region of the SERT gene (the 5HTTLPR; [39,41]). The SERT is the carrier protein that is responsible for reuptake of 5-HT into presynaptic terminals, thus terminating 5-HT signalling [42]. Expression of the long allele of the 5HTTLPR is associated with an approximate two fold higher uptake of 5-HT compared to other genotype expressions [43]. As action of the SERT constitutes a fundamental mechanism for the regulation of 5-HT levels in the central nervous system, the rapid 5-HT uptake associated with the long variant of 5HTTLPR results in reduced availability of active 5-HT [44].

While genetic evidence points towards a dysfunction at the level of the SERT in ADHD, *in vivo* evidence for altered SERT expression and availability in ADHD patients is currently inconclusive. Early PET investigations assessing binding potentials for ligands with high specificity for SERT showed no difference in SERT availability between ADHD patients and healthy controls [45,46]. Recently, however, Vanicek et al. [47] has argued that these studies lacked the required statistical power to detect differences between groups. Vanicek et al. [47] performed a PET interregional molecular correlational analysis to assess functional connectivity between various regions of interest that are traditionally implicated in the neuropathology of ADHD. They found altered interregional SERT binding between various regions of ADHD patients compared to healthy controls. As SERT expression *in vivo* is partially regulated by 5-HT release [48], these findings point towards altered 5-HT dynamics in ADHD.

There are thus clear contradictions within the literature assessing the contribution of the serotonergic system to ADHD symptoms. Other than a single open-label trial [28], clinical reports suggest that mono-therapeutic interventions targeting 5-HT in ADHD are either

ineffective, or otherwise exacerbate symptoms [35,36]. However, genetic and biological evidence point towards dysfunction at the level of the serotonergic system [39]. We have argued above that collicular dysfunction underlies distractibility in ADHD and have presented pharmacological evidence that psychostimulants may reduce distractibility in ADHD by targeting 5-HT transmission at the level of the SC. In light of this biological and genetic evidence, it is somewhat paradoxical that clinical reports suggest that drugs targeting 5-HT are of limited efficacy when the treating the symptoms of ADHD. One potential explanation for this disconnect is that the contribution of 5-HT to the pathology of ADHD is more complex than an overall increase or decrease in symptom presentation. In a review of serotonergic dysfunction in ADHD, Oades [49] proposed that while a widespread association of 5-HT dysfunction with a diagnosis of ADHD is unlikely, there may be a differential contribution of 5-HT to the major symptomatic domains of ADHD. Evidence reviewed showed little association between 5-HT and hyperkinetic ADHD symptoms, but did show an association between 5-HT and inattentive symptoms. In particular, Oades [49] proposed that reduced 5-HT availability in ADHD contributes to altered perceptual sensitivity and salience designation, leading to enhanced cognitive impulsivity and distractibility. If 5-HT only has relevance to attentional symptoms, this may explain the mixed results presented in the clinical trials above, where specific symptomatic domains were not controlled for. While this proposition may contextualise why *D*-amphetamine affects 5-HT transmission in salience designation circuits such as the SC, it does not explain why 5-HT based interventions are not more efficacious in the treatment of ADHD, particularly for inattentive symptoms (e.g. [50]).

A more viable explanation for clinical reports suggesting that 5-HT is of limited relevance to the pharmacotherapy of ADHD relates to the regulatory mechanisms that control 5-HT neurotransmission *in vivo*. It has long been known in the depression literature that a minimum of 3–4 weeks of continuous daily SSRI use is required until improvements in clinical symptoms are observed [51]. Similarly, when SSRIs are used in the treatment of obsessive compulsive disorder (OCD), a minimum period 8–12 weeks of continuous daily SSRI use is required until a clinically and statistically significant improvement in symptoms is observed [34,52]. This delay in time to response is believed to result from feedback mechanisms at the level of the raphe nuclei, the major source of ascending 5-HT projections for the central nervous system [53,54], which act to regulate the rate of 5-HT release in target regions [51]. Consequently, it is only after chronic regular exposure to SSRIs that these regulatory feedback mechanisms are desensitised, allowing for increased levels of synaptic 5-HT and commensurate therapeutic benefits. In the trials assessing SSRI use for ADHD described above, SSRIs were prescribed either for short periods (three weeks for Findling [30]; six weeks for Barrickman et al., [25]), or were otherwise not administered daily [29,31]. Given that up to twelve weeks of continuous daily SSRI use is required to desensitise raphe feedback mechanisms and allow for observable clinical improvements in other disorders (e.g. OCD; [52]), it is plausible that participants in the ADHD clinical trials described above were not administered SSRIs for sufficient regularity and length for any potential clinical effect on ADHD symptoms. As these trials represent a basis for which SSRIs are considered to have limited pharmacological relevance to ADHD (e.g. [35]), it is possible that by bypassing the mechanisms that regulate 5-HT release, we may observe effects of SSRIs which have clinical relevance to the pharmacotherapy ADHD. The next section will thus consider the principal mechanism that regulates the release of 5-HT, and a potential strategy for bypassing this mechanism.

### Serotonin based interventions for ADHD: Autoregulation of serotonergic activity

The delayed onset of the therapeutic benefits of SSRIs observed in both depression and OCD can be explained by regulatory mechanisms

of somatodendritic autoreceptors situated on 5-HT cells in the raphe nuclei, which decrease the firing rate of 5-HT neurons in response to locally released 5-HT. Serotonergic neurons in the dorsal and medial raphe nuclei (DRN and MRN) form the majority of all 5-HT producing cells within the central nervous system, with the DRN and MRN accounting for up to 85% and 15% of all serotonergic cell bodies respectively [55]. Neurons in the DRN give rise to ascending projections to a broad range of cortical and subcortical targets, including the cerebral cortex, basal ganglia, and limbic system [56], and of particular relevance to the present discussion, the SC [57]. The firing rate of raphe neurons alters the release of 5-HT in target regions [58]. Consequently, the mechanisms that regulate the firing of these DRN neurons thus regulate 5-HT release and availability at afferent targets. The most relevant of these mechanisms to the delayed efficacy SSRIs pharmacotherapy is the down-regulation of DRN firing elicited by somatodendritic 5-HT<sub>1A</sub> autoreceptors.

Under typical conditions, 5-HT neurons exhibit spontaneous firing at a rate of 1–5 action potentials per second [59]. When DRN neurons are exposed to 5-HT, either through local dendrodendritic connections or raphe-raphe projections [60], inhibitory post synaptic potentials can be observed, resulting in down-regulation of DRN activity and thus reduced central nervous system 5-HT release [61]. A major contributor to this down-regulation is negative feedback evoked by 5-HT<sub>1A</sub> autoreceptors [58,62]. 5-HT<sub>1A</sub> autoreceptors are a class of G protein-coupled receptors which are densely expressed on somatodendritic compartments of raphe nuclei cell bodies [63]. Upon binding with 5-HT, these autoreceptors activate G protein-coupled inwardly rectifying potassium channels, thereby increasing permeability to K<sup>+</sup> and thus causing membrane hyperpolarisation and a consequent reduction in neural excitability [64,65].

It has long been recognised that acute SSRI administration increases extracellular 5-HT availability in the DRN, thereby activating 5-HT<sub>1A</sub> autoreceptors and reducing the firing rate of neurons mediated by these autoreceptors [66]. As a result, 5-HT release is inhibited in areas innervated by these DRN neurons [67]. Consequently, the delayed time to response observed when SSRIs are administered clinically (for e.g. in depression) can be explained by desensitisation of 5-HT<sub>1A</sub> autoreceptors following consistent daily use over a number of weeks [68]. In terms of 5-HT availability at afferent DRN targets, it can be conceptualised that any initial increase in synaptic 5-HT availability caused by SSRIs occupying presynaptic 5-HT transporters is counteracted by the down-regulation of DRN firing rate by 5-HT<sub>1A</sub> autoreceptors. Following desensitisation of these autoreceptors, negative feedback at the level of the raphe is reduced, thereby normalising firing rate and allowing for increased 5-HT availability in afferent target regions. This conceptualisation is supported by evidence that more rapid onset of antidepressant effects of SSRIs can be obtained when SSRIs are administered concurrently with a 5-HT<sub>1A</sub> antagonist [69]. Similarly, selective deactivation of 5-HT<sub>1A</sub> autoreceptors in murine models allows for immediate anti-depressant effect following a single dose of fluoxetine [70]. This concept can be expanded to allow for the examination of effects of SSRIs in acute animal preparations. Pre-treatment with 5-HT<sub>1A</sub> antagonists prior to administration of fluoxetine has allowed for the exploration of a variety of behavioural and pharmacological effects which would have otherwise been obscured by the autoregulation of DRN activity (e.g. [66,71,72]).

One potential problem for the proposal that insufficient 5-HT<sub>1A</sub> autoreceptor desensitisation might underlie the previous lack of effectiveness of SSRIs in the treatment of ADHD is that the classical psychostimulant pharmacotherapeutic agents used in the disorder, *D*-amphetamine and methylphenidate, do not require extended exposure before they become effective (e.g. [73,74]) (as we have argued is likely to be the case for SSRIs), even though they too are likely to lead to elevated levels of 5-HT in the DRN, which should activate inhibitory 5-HT<sub>1A</sub> receptors on the cell bodies of raphe neurons. Why might they not require a period of time to desensitise 5-HT<sub>1A</sub> receptors before

becoming effective? In the case of D-amphetamine, the explanation is fairly straightforward, since the drug produces the impulse-independent release of monoamine neurotransmitters (e.g. [75]), hence the elevation of forebrain 5-HT levels is still likely to occur following D-amphetamine administration even if DRN firing rate is acutely suppressed. The case for methylphenidate is a more complicated, since there is no direct evidence of impulse-independent release as far as we are aware. However, evidence from freely moving animals suggests that acute methylphenidate administration changes that activity of over half of the neurons in the DRN, in most cases increasing their firing rate [76]. Although the mechanism of action is unknown, again this means the drug is likely to produce an early increase in forebrain 5-HT levels without the need for a period of desensitisation.

We have previously presented evidence outlining the potential benefits of exploiting collicular 5-HT transmission in the treatment of ADHD. The critical role of 5-HT<sub>1A</sub> auto-receptors in regulating 5-HT transmission suggests that the efficacy of SSRIs in the treatment of ADHD can be improved by combining SSRIs with the administration of 5-HT<sub>1A</sub> antagonists. Antagonism of 5-HT<sub>1A</sub> receptors is unlikely to directly interfere with the therapeutically desired inhibitory effects of 5-HT on collicular activity as this appears to be mediated by 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> and receptors [57,77].

### Summary and next steps

There is a disconnect between pre-clinical evidence, which suggests that SSRI-based therapies for ADHD are likely to be effective, and clinical reports which suggest that SSRIs are of limited therapeutic relevance to the treatment of ADHD. We propose that this disconnect can be explained by inadequate control of autoregulation processes, which paradoxically limit the availability of 5-HT when SSRIs are administered over the irregular periods used in these clinical trials [30,31]. As such, we argue that the participants in earlier trials were not administered SSRIs with sufficient regularity or for long enough to fully realise any potential benefits of targeting 5-HT in the pharmacotherapy of ADHD. In light of this, there may be under-researched potential to exploit 5-HT transmission therapeutically in ADHD, by administering SSRIs according to a regime which desensitises 5-HT<sub>1A</sub> auto-receptors. Hence, we suggest that combination therapies linking SSRIs and 5-HT<sub>1A</sub> antagonists are a potential way forward in the development of efficacious non-addictive pharmacotherapies for ADHD. The need to develop new efficacious non-addictive pharmacotherapies for ADHD is made even more acute by the recent evidence that not only do ADHD symptoms persist into adulthood in up to 43% of childhood cases [78], but ADHD can also emerge de novo in adulthood [79]. Introducing a combination therapy may be relatively straightforward as the centrally-active 5-HT<sub>1A</sub> partial agonist pindolol (Visken) is already in clinical use for unrelated conditions in physical medicine [80], and drugs like the 5-HT<sub>1A</sub> antagonist lecozotan have been developed in the context of Alzheimer's disease [81], so their adoption in the context of ADHD would represent a repurposing of existing medications rather than the generation additional drugs. However, recent studies with SSRI-resistant depression underline the critical issue of dose when it comes to incorporating an adjunct therapy into a treatment regime alongside SSRIs [82]. It is also important to bear in mind the costs and benefits of such adjunct therapies. As a monotherapy in ADHD, very high dose pindolol (20 mg b.i.d.) has recently been shown to be as effective as a standard dose of methylphenidate against conduct problems and hyperactive behaviour at home and hyperactivity at school, although adverse effects were greater [83]. The extent to which those effects might be ameliorated via reducing the dose, and/or the combined administration of pindolol and SSRIs has yet to be determined.

### Declaration of Competing Interest

The authors declare that they have no known competing financial

interests or personal relationships that could have appeared to influence the work reported in this paper.

### References

- [1] Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition? *World Psychiatry* 2003;2(2):104–13.
- [2] Himmelstein J, Newcorn JH, Halperin JM. The neurobiology of attention-deficit hyperactivity disorder. *Front Biosci* 2000;5:D461–78.
- [3] NICE Guideline NG87: Attention deficit hyperactivity disorder: diagnosis and management. Published March 2018. Accessed 13:03:19.
- [4] Williams RJ, Goodale LA, Shay-Fiddler MA, Gloster SP, Chang SY. Methylphenidate and dextroamphetamine abuse in substance-abusing adolescents. *J Addict* 2004;13(4):381–9.
- [5] Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. *Am J Psychiatry* 2008;165(6):721–30.
- [6] Werner H, Strauss A. Causal factors in low performance. *Am J Mental Defic* 1940;45:213–8.
- [7] Wilens TE, Biederman J, Faraone SV, Martelon M, Westerberg D, Spencer TJ. Presenting ADHD symptoms, subtypes, and comorbid disorders in clinically referred adults with ADHD. *J Clin Psychiatry* 2009;70(11):1557–62.
- [8] Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. *Am J Psychiatry* 2000;157(5):816–8.
- [9] Overton PG. Collicular dysfunction in attention deficit hyperactivity disorder. *Med Hypotheses* 2008;70(6):1121–7.
- [10] Dean P, Redgrave P, Westby GW. Event or emergency? Two response systems in the mammalian superior colliculus. *Trends Neurosci* 1989;12(4):137–47.
- [11] Clements KM, Devonshire IM, Reynolds JN, Overton PG. Enhanced visual responses in the superior colliculus in an animal model of attention-deficit hyperactivity disorder and their suppression by D-amphetamine. *Neuroscience* 2014;274:289–98.
- [12] Brace LR, Kraev I, Rostron CL, Stewart MG, Overton PG, Dommert EJ. Altered visual processing in a rodent model of Attention-Deficit Hyperactivity Disorder. *Neuroscience* 2015;303:364–77.
- [13] Panagiotidi M, Overton P, Stafford T. Increased microsaccade rate in individuals with ADHD traits. *J Eye Movem Res* 2017;10(1).
- [14] Goffart L, Hafed ZM, Krauzlis RJ. Visual fixation as equilibrium: evidence from superior colliculus inactivation. *J Neurosci* 2012;32:10627–36.
- [15] Panagiotidi M, Overton PG, Stafford T. Multisensory integration and ADHD-like traits: evidence for an abnormal temporal integration window in ADHD. *Acta Psychol (Amst)* 2017;181:10–7.
- [16] Meredith MA, Stein BE. Visual, auditory, and somatosensory convergence on cells in superior colliculus results in multisensory integration. *J Neurophysiol* 1986;56:640–62.
- [17] Easton N, Steward C, Marshall F, Fone K, Marsden C. Effects of amphetamine isomers, methylphenidate and atomoxetine on synaptosomal and synaptic vesicle accumulation and release of dopamine and noradrenaline in vitro in the rat brain. *Neuropharmacology* 2007;52(2):405–14.
- [18] Holmes JC, Rutledge CO. Effects of the d- and l-isomers of amphetamine on uptake, release and catabolism of norepinephrine, dopamine and 5-hydroxytryptamine in several regions of rat brain. *Biochem Pharmacol* 1976;25(4):447–51.
- [19] Kuczenski R, Segal D. Concomitant characterization of behavioral and striatal neurotransmitter response to amphetamine using in vivo microdialysis. *J Neurosci* 1989;9(6):2051–65.
- [20] Parent A, Descarries L, Beaudet A. Organization of ascending serotonin systems in the adult rat brain. A radioautographic study after intraventricular administration of [3H]5-hydroxytryptamine. *Neuroscience* 1981;6(2):115–38.
- [21] Wichmann T, Starke K. Uptake, release, and modulation of release of noradrenaline in rabbit superior colliculus. *Neuroscience* 1988;26(2):621–34.
- [22] Bolton AD, Murata Y, Kirchner R, et al. A diencephalic dopamine source provides input to the superior colliculus, where D1 and D2 receptors segregate to distinct functional zones. *Cell Rep* 2015;13(5):1003–15.
- [23] Pan D, Gatley SJ, Dewey SL, et al. Binding of bromine-substituted analogs of methylphenidate to monoamine transporters. *Eur J Pharmacol* 1994;264(2):177–82.
- [24] Dommert EJ, Overton PG, Greenfield SA. Drug therapies for attentional disorders alter the signal-to-noise ratio in the superior colliculus. *Neuroscience* 2009;164(3):1369–76.
- [25] Hooker JM, Kim SW, Reibel AT, Alexoff D, Xu Y, Shea C. Evaluation of [(11C) metergoline as a PET radiotracer for 5HT<sub>1A</sub> in nonhuman primates. *Bioorg Med Chem* 2010;18(22):7739–45.
- [26] Chivers JK, Hall MD, Kelly E, Jenner P, Marsden CD. Dopamine receptor binding site binding sites in the rat superior colliculus. *J Pharm Pharmacol* 1984;36(7):484–8.
- [27] Carginale V, Capasso A, Madonna L, Borrelli L, Parisi E. Adenylate cyclase from sea urchin eggs is positively and negatively regulated by D-1 and D-2 dopamine receptors. *Exp Cell Res* 1992;203(2):491–4.
- [28] Barrickman L, Noyes R, Kuperman S, Schumacher E, Verda M. Treatment of ADHD with fluoxetine: a preliminary trial. *J Am Acad Child Adolesc Psychiatry* 1991;30(5):762–7.
- [29] Donnelly M, Rapoport JL, Potter WZ, Oliver J, Keyser CS, Murphy DL. Fenfluramine and dextroamphetamine treatment of childhood hyperactivity. Clinical and biochemical findings. *Arch Gen Psychiatry* 1989;46(3):205–12.
- [30] Findling RL. Open-label treatment of comorbid depression and attentional disorders

- with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: a case series. *J Child Adolesc Psychopharmacol* 1996;6(3):165–75.
- [31] Garland EJ. Reviews: Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats. *J Psychopharmacol* 1998;12(4):385–95.
- [32] Riddle MA, King RA, Hardin MT, et al. Behavioral side effects of fluoxetine in children and adolescents. *J Child Adolesc Psychopharmacol* 1990;1(3):193–8.
- [33] Popper CW. Antidepressants in the treatment of attention-deficit/hyperactivity disorder. *J Clin Psychiatry* 1997;58(Suppl. 14):14–29.
- [34] Pittenger C, Bloch MH. Pharmacological treatment of obsessive-compulsive disorder. *Psychiatric Clin N America* 2014;37(3):375–91.
- [35] Pliszka SR. The neuropsychopharmacology of attention-deficit/hyperactivity disorder. *Biol Psychiatry* 2005;57(11):1385–90.
- [36] Spencer TJ, Biederman J, Wilens TE, Faraone SV. Novel treatments for attention-deficit/hyperactivity disorder in children. *J Clin Psychiatry* 2002;63(Suppl. 12):16–22.
- [37] Faraone SV, Biederman J, Spencer T, et al. Efficacy of atomoxetine in adult attention-Deficit/Hyperactivity Disorder: a drug-placebo response curve analysis. *Behav Brain Funct* 2005;1(1):16.
- [38] Garmock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. *Paediatr Drugs* 2009;11(3):203–26.
- [39] Gizer IR, Ficks C, Waldman ID. Candidate gene studies of ADHD: a meta-analytic review. *Hum Genet* 2009;126(11):51–90.
- [40] McGough JJ, McCracken JT, Loo SK, et al. A candidate gene analysis of methylphenidate response in attention-deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry* 2009;48(12):1155–64.
- [41] Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention-deficit/hyperactivity disorder. *Biol Psychiatry* 2005;57(11):1313–23.
- [42] Heils A, Teufel A, Petri S, et al. Allelic variation of human serotonin transporter gene expression. *J Neurochem* 1996;66(6):2621–4.
- [43] Retz W, Retz-Junginger P, Supprian T, Thome J, Rösler M. Association of serotonin transporter promoter gene polymorphism with violence: relation with personality disorders, impulsivity, and childhood ADHD psychopathology. *Behav Sci Law* 2004;22(3):415–25.
- [44] Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. *Science* 1996;274(5292):1527–31.
- [45] Hesse S, Ballaschke O, Barthel H, Sabri O. Dopamine transporter imaging in adult patients with attention-deficit/hyperactivity disorder. *Psychiatry Res* 2009;171(2):120–.
- [46] Karlsson L, Tuominen L, Huotari A, et al. Serotonin transporter in attention-deficit hyperactivity disorder—preliminary results from a positron emission tomography study. *Psychiatry Res* 2013;212(2):164–5.
- [47] Vanicek T, Kutzelnigg A, Philippe C, et al. Altered interregional molecular associations of the serotonin transporter in attention deficit/hyperactivity disorder assessed with PET. *Hum Brain Mapp* 2017;38(2):792–802.
- [48] Benmansour S, Owens WA, Cecchi M, Morilak DA, Frazer A. Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter. *J Neurosci* 2002;22(15):6766–72.
- [49] Oades RD. Role of the serotonin system in ADHD: treatment implications. *Expert Rev Neurother* 2007;7(10):1357–74.
- [50] Kratochvil CJ, Newcorn JH, Arnold LE, et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. *J Am Acad Child Adolesc Psychiatry* 2005;44(9):915–24.
- [51] Briley M, Moret C. Neurobiological mechanisms involved in antidepressant therapies. *Clin Neuropharmacol* 1993;16(5):387–400.
- [52] Issari Y, Jakubovski E, Bartley CA, Pittenger C, Bloch MH. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis. *J Clin Psychiatry* 2016;77(5):e605–11.
- [53] Vertes RP. A PHA-L analysis of ascending projections of the dorsal raphe nucleus in the rat. *J Comp Neurol* 1991;313(4):643–68.
- [54] Vertes RP, Fortin WJ, Crane AM. Projections of the median raphe nucleus in the rat. *J Comp Neurol* 1999;407(4):555–82.
- [55] Hornung J-P. The human raphe nuclei and the serotonergic system. *J Chem Neuroanat* 2003;26(4):331–43.
- [56] Cools R, Roberts AC, Robbins TW. Serotonergic regulation of emotional and behavioural control processes. *Trends Cogn Sci* 2008;12(1):31–40.
- [57] Mooney RD, Huang X, Shi MY, Bennett-Clarke CA, Rhoades RW. Serotonin modulates retinotectal and corticotectal convergence in the superior colliculus. *Prog Brain Res* 1996;112:57–69.
- [58] Maejima T, Maseck OA, Mark MD, Herlitze S. Modulation of firing and synaptic transmission of serotonergic neurons by intrinsic G protein-coupled receptors and ion channels. *Front Integr Neurosci* 2013;7:40.
- [59] Aghajanian GK, Vandermaelen CP. Intracellular recordings from serotonergic dorsal raphe neurons: pacemaker potentials and the effect of LSD. *Brain Res* 1982;238(2):463–9.
- [60] Adell A, Celada P, Abellan MT, Artigas F. Origin and functional role of the extracellular serotonin in the midbrain raphe nuclei. *Brain Res Brain Res Rev* 2002;39(2–3):154–80.
- [61] Morikawa H, Manzoni OJ, Crabbe JC, Williams JT. Regulation of central synaptic transmission by 5-HT(1B) auto- and heteroreceptors. *Mol Pharmacol* 2000;58(6):1271–8.
- [62] Fischer AG, Jocham G, Ullsperger M. Dual serotonergic signals: a key to understanding paradoxical effects? *Trends Cogn Sci*. 2014. pii: S1364-6613(14)00237-X.
- [63] McDevitt RA, Neumaier JF. Regulation of dorsal raphe nucleus function by serotonin autoreceptors: a behavioral perspective. *J Chem Neuroanat* 2011;41(4):234–46.
- [64] Penington NJ, Kelly JS, Fox AP. Whole-cell recordings of inwardly rectifying K<sup>+</sup> currents activated by 5-HT<sub>1A</sub> receptors on dorsal raphe neurones of the adult rat. *J Physiol* 1993;469:387–405.
- [65] Stamford JA, Davidson C, McLaughlin DP, Hopwood SE. Control of dorsal raphe 5-HT function by multiple 5-HT(1) autoreceptors: parallel purposes or pointless plurality? *Trends Neurosci* 2000;23(10):459–65.
- [66] Gartside SE, Umbers V, Hajós M, Sharp T. Interaction between a selective 5-HT<sub>1A</sub> receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. *Br J Pharmacol* 1995;115(6):1064–70.
- [67] Gardier AM, Malagie I, Trillat AC, Jacquot C, Artigas F. Role of 5-HT<sub>1A</sub> autoreceptors in the mechanism of action of serotonergic antidepressant drugs: recent findings from in vivo microdialysis studies. *Fundam Clin Pharmacol* 1996;10(1):16–27.
- [68] Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. *J Affect Disord* 1998;51(3):215–35.
- [69] Ballesteros J, Callado LF. Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials. *J Affect Disord* 2004;79(1):137–47.
- [70] Bortolozzi A, Castane A, Semakova J, et al. Selective siRNA-mediated suppression of 5-HT<sub>1A</sub> autoreceptors evokes strong anti-depressant-like effects. *Mol Psychiatry* 2012;17(6):612–23.
- [71] Cassani J, Dorantes-Barron AM, Novales LM, Real GA, Estrada-Reyes R. Anti-depressant-like effect of kaempferitrin isolated from *Justicia spicigera* Schldtl (Acanthaceae) in two behavior models in mice: evidence for the involvement of the serotonergic system. *Molecules* 2014;19(12):21442–61.
- [72] Palucha-Poniewiera A, Branski P, Wieronska JM, Stachowicz K, Slawinska A, Pilc A. The antidepressant-like action of mGlu<sub>5</sub> receptor antagonist, MTEP, in the tail suspension test in mice is serotonin dependent. *Psychopharmacology* 2014;231(1):97–107.
- [73] Spencer T, Wilens T, Biederman J, Faraone SV, Ablon JS, Lapey K. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. *Arch Gen Psychiatry* 1995;52(6):434–43.
- [74] Taylor FB, Russo J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. *J Child Adolesc Psychopharmacol* 2000;10(4):311–20.
- [75] Floor E, Meng L. Amphetamine releases dopamine from synaptic vesicles by dual mechanisms. *Neurosci Lett* 1996;215(1):53–6.
- [76] Tang B, Dafny N. Dorsal raphe neuronal activities are modulated by methylphenidate. *J Neural Transm* 2013;120(5):721–31.
- [77] Boulenguez P, Foreman N, Chauveau J, Segu L, Buhot MC. Distractibility and locomotor activity in rat following intra-collicular injection of a serotonin 1B–1D agonist. *Behav Brain Res* 1995;67:229–39.
- [78] Spencer TJ, Biederman J, Wilens TE, Faraone SV. Overview and neurobiology of attention-deficit/hyperactivity disorder. *J Clin Psychiatr*. 2002;63(Suppl. 12):3–9.
- [79] Moffitt TE, Houts R, Asherson P, et al. Is adult ADHD a childhood-onset neurodevelopmental disorder? Evidence from a four-decade longitudinal cohort study. *Am J Psychiatry* 2015;172:967–77.
- [80] Wong GW, Boyda HN, Wright JM. Blood pressure lowering efficacy of partial agonist beta blocker monotherapy for primary hypertension. *Cochrane Database Syst Rev* 2014;11(11). CD007450.
- [81] Childers WE, Harrison BL, Abou-Gharbia MA, et al. Lecozotan hydrochloride – cognition enhancer treatment of Alzheimer's disease competitive 5-HT<sub>1A</sub> receptor antagonist. *Drugs Fut* 2005;32(5):399–407.
- [82] Liu Y, Zhou X, Zhu D, et al. Is pindolol augmentation effective in depressed patients resistant to selective serotonin reuptake inhibitors? A systematic review and meta-analysis. *Hum Psychopharmacol*. 2015;30:132–42.
- [83] Buitelaar JK, van der Gaag RJ, Swaab-Barneveld H, Kuiper M. Pindolol and methylphenidate in children with attention-deficit hyperactivity disorder. Clinical efficacy and side-effects. *J Child Psychol Psychiatry* 1996;37:587–95.